Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are hovering over the Pharmalot campus, but our spirits remain sunny, nonetheless.
And why not? As the Morning Mayor suggested to us long ago, “Every day should be unwrapped like a precious gift.” While you tug on the ribbon, we will fire up the trusty kettle for a cuppa ginger honey.
Of course, you are invited to join us. Remember, no prescription is required.
This is strictly cash money. Meanwhile, here are a few items of interest.
Hope you have a meaningful and productive day and, of course, do stay in touch. … The Trump administration has prepared an order to impose a 100% tariff on imports of patented medicines and their active ingredients , STAT writes.
The tariffs could be announced as soon as Thursday, but the timeline or details could change. The order offers several options for drugmakers to avoid the tariffs, which will not apply to companies that have struck “most-favored nation” deals to sell drugs in the U.S.
The decision timeline is fluid, with potential announcements as soon as Thursday and several off-ramps for manufacturers.
The plan includes pathways to mitigate tariff impact, including maintaining MFN-equivalent pricing arrangements with certain countries for the duration of the president’s term, and options to reduce tariffs to 20% for firms relocating production domestically, contingent on approval by the U.S.
Secretary of Health and Human Services.
The higher tariff would resume by 2030.
The approval occurred under a new FDA voucher program designed to expedite reviews for drugs aligned with national health priorities.
The development comes amid anticipated competition with Novo Nordisk’s Wegovy, a GLP-1–based injectable.
The interaction with MFN pricing agreements and the conditional 20% tariff for onshoring activities reflects a strategy to balance affordability, supply resilience, and political objectives during the current administration’s term.
The voucher-based acceleration indicates alignment with national health priorities and may affect market timing and payer dynamics.
The Wegovy reference underscores a competitive landscape between oral and injectable modalities in obesity management.
Production relocation to the U.S.
reduces tariff to 20% temporarily, with a staged return to 100% by 2030.
The forecasted tariff timeline and implementation specifics were described as potentially subject to change.